US stock futures muted as rate cut bets wane ahead of Jackson Hole
On Thursday, Raymond (NSE:RYMD) James reiterated its positive stance on Phreesia Inc . (NYSE:PHR), maintaining an Outperform rating and a $30.00 price target. Currently trading at $23.30, the stock appears undervalued according to InvestingPro analysis, with analyst targets ranging from $28 to $35. The firm’s analysts highlighted Phreesia’s recent performance, noting a quarter marked by impressive 17.8% revenue growth and stronger-than-expected margins, including a robust 67.9% gross profit margin. The analysts expressed confidence in the company’s financial discipline and strategic investments in innovation, which they expect to continue contributing positively to the company’s financials.
Phreesia’s recent financial results have shown that the company is capable of exceeding expectations in revenue and margins. With a market capitalization of $1.39 billion and maintaining a healthy current ratio of 1.78, the company demonstrates solid financial management. Raymond James analysts have projected an adjusted EBITDA of $236 million and a free cash flow (FCF) of $212 million for the fiscal year 2029 (calendar year 2028). InvestingPro data reveals several additional positive indicators, with 3 analysts recently revising their earnings estimates upward. These projections suggest a free cash flow multiple of approximately 7.2 times based on the fiscal year 2029 figures, equating to a 16.5% free cash flow yield.
The analysts’ commentary underscores Phreesia’s ability to maintain a profitable growth trajectory. Despite the uncertain economic environment, the company’s fundamentals are seen as robust, with the potential to continue growing earnings into the latter half of the decade. Operating with a moderate level of debt and a strong Altman Z-Score of 3.4, Phreesia maintains a solid financial position. Discover more detailed insights about PHR’s financial health and growth potential in the comprehensive Pro Research Report, available exclusively on InvestingPro. According to the analysts, Phreesia’s disciplined approach to expenses, coupled with its strategic investments, positions it well for sustained earnings growth.
Phreesia’s focus on innovation was also emphasized as a key driver of its success. The company’s strategic investments in new technologies and services are expected to support its growth and profitability. With a favorable outlook on the company’s future, Raymond James analysts believe that Phreesia is well-equipped to navigate through any macroeconomic volatility and capitalize on opportunities to enhance its earnings.
In summary, Raymond James has affirmed its confidence in Phreesia Inc., citing the company’s solid financial performance and promising prospects for continued earnings growth. The reaffirmed Outperform rating and $30.00 price target reflect the firm’s optimistic view of Phreesia’s position in the market and its potential for future success.
In other recent news, Phreesia Inc. reported its first-quarter earnings, surpassing expectations with a revenue of $115.9 million, a 15% year-over-year increase. The company’s earnings per share were reported at -$0.07, better than the anticipated -$0.12. Phreesia also exceeded forecasts for adjusted EBITDA, which stood at $20.8 million, reflecting a margin of 18%. The company has maintained its revenue guidance for fiscal year 2026, projecting between $472 million and $482 million, while raising its adjusted EBITDA guidance to a range of $85 million to $90 million.
Analysts have responded positively to these developments. Piper Sandler maintained an Overweight rating on Phreesia with a $33 price target, citing the company’s strong financial performance and increased guidance. Similarly, JPMorgan reaffirmed its Overweight rating with a $30 price target, noting the company’s healthy growth rate and expanded client base. However, Citi adjusted its price target from $35 to $33, while still keeping a Buy rating, acknowledging some slower growth in certain segments but overall solid results.
Phreesia continues to focus on AI and product innovation as central to its strategy, contributing to its robust financial performance. The company’s integration with electronic health record systems and its extensive network of healthcare service centers remain key factors in its success. These recent developments highlight Phreesia’s ongoing efforts to enhance operational efficiency and drive growth in the healthcare technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.